Quotables
"I think there is a world market for maybe five computers."
Thomas Watson, chairman of IBM ; 1943
PatentStorm News
Make the Most of Our Site
See this month's Top Inventors and Most Cited Patents.
Stay on top of the latest innovations by subscribing to an RSS feed.
Registered users: Manage your profile.
| Application No. | Application Title | Issue Date |
| 20100279941 | CD36 MODULATION AND USES THEREOF Methods, uses, kits and products are described for the prevention and treatment of ischemia-associated cardiopathies such as myocardial ischemia/reperfusion (I/R) injury, based on the selective modulation of CD36.... | 11/04/2010 |
| 20100261652 | Tissue Adhesive Using Engineered Proteins There is provided in one embodiment of the disclosure a tissue adhesive composition comprising an engineered protein having repeated blocks of an elastin domain and at least one cell-binding domain and further comprising a polymer crosslinker. When the engineered protei... | 10/14/2010 |
| 20100233161 | NOVEL MULTIFUNCTIONAL COMPOUNDS FOR PHARMACEUTICAL PURPOSES The invention relates to a synthetic bifunctional non-antibody compound comprising one or more effector moieties and one or more binder moieties, wherein the effector moieties are operably linked to the binder moieties via a linker, the effector moieties are ligands to ... | 09/16/2010 |
| 20100233262 | COATED TABLET A main object of the present invention is to provide a novel coated tablet which contains a drug having a guanidino group and does not suffer an obvious color change even when packed in a one-dose pack together with a drug having a (5-methyl-2-oxo-1,3-dioxol-4-yl)methyl... | 09/16/2010 |
| 20100226911 | Treating or preventing extracellular matrix build-up A method of treatment for treating, preventing, inhibiting or reducing extracellular matrix build-up in a body tissue or a bodily fluid transport vessel, in a subject, includes administering to a subject in need of such treatment an effective amount of a composition inc... | 09/09/2010 |
| 20100226969 | COMPOUNDS FOR INHIBITING PROTEIN AGGREGATION, AND METHODS FOR MAKING AND USING THEM The invention provides compositions comprising protein aggregation inhibitors, and pharmaceutical compositions comprising them, and methods for making and using them, including methods for preventing, reversing, slowing or inhibiting protein aggregation, e.g., for treat... | 09/09/2010 |
| 20100226916 | COMPOSITIONS AND METHODS FOR TREATING OCULAR DISEASES AND CONDITIONS The present invention relates to compositions and methods for prevention and treatment of diseases and conditions, particularly ocular diseases and conditions, characterized by aberrant fibrogenesis or scarring, inflammation, and/or aberrant neovascularization or angiog... | 09/09/2010 |
| 20100222281 | DELIVERY OF HYDROPHILIC DRUGS Compositions comprising a lipophilic derivative of a hydrophilic drug and an amphiphile compound for use in therapy of the human or animal body are provided. Methods of medical treatment, wherein a composition according to the invention is administered to a human or ani... | 09/02/2010 |
| 20100215583 | CELL NUCLEUS-ENTERING COMPOSITIONS A pharmaceutically acceptable composition and method for entering a cell nucleus utilizes a cell nucleus-entering polypeptide including at least one of amino acid sequence LKKTET (SEQ ID NO: 1), amino acid sequence LKKTNT (SEQ ID NO: 2) or amino acid sequence KSKLKK (SE... | 08/26/2010 |
| 20100215614 | Enterostatin as Inhibitor of Angiogenesis It has been discovered that enterostatin inhibits angiogenesis in an in vitro adipose tissue angiogenesis model. In concentrations from about 10−6 to about 10−9 M, enterostatin effectively blocked the angiogenic response. Enterostatin will be e... | 08/26/2010 |
| 20100216701 | Protein Kinase C Inhibitors for Prevention of Insulin Resistance and Type 2 Diabetes The present invention provides peptides and peptide analogs capable of inhibiting the activity of protein kinase C. The invention discloses use of such peptides and analogs for preparation of pharmaceutical compositions and methods for prevention, delay, suppression or ... | 08/26/2010 |
| 20100210566 | AZAPEPTIDES AS CD36 BINDING COMPOUNDS An azapeptide derivative of growth hormone releasing peptide (GHRP) of Formula I: A-(Xaa)a-N(RA)—N(RB)—C(O)-(Xaa′)b-B which binds to CD 36.... | 08/19/2010 |
| 20100210560 | NEUROTENSIN RECEPTOR AGONISTS AND OPIOID RECEPTOR AGONISTS This document provides methods and materials for treating pain. For example, this document provides methods that involve administering a neurotensin receptor (NTR) agonist and an opioid receptor agonist to a mammal (e.g., a human). Compositions containing an NTR agonist... | 08/19/2010 |
| 20100210561 | USE OF PEPTIDE AS A THERAPEUTIC AGENT The present invention is directed to the use of the peptide compound Tyr-D-Cys(tBu)-Gly-Phe-Leu-Thr(tBu)-OH as a therapeutic agent for the prophylaxis and/or treatment of cancer, autoimmune diseases, fibrotic diseases, inflammatory diseases, neurodegenerative diseases, ... | 08/19/2010 |
| 20100209467 | TDF-RELATED COMPOUNDS AND ANALOGS THEREOF, ANALOGS AND BIOACTIVE FRAGMENTS The present invention relates generally to tissue differentiation factor (TDF) analogs. More specifically, the invention relates to structure-based methods and compositions useful in designing, identifying, and producing molecules, which act as functional modulators of ... | 08/19/2010 |
| 20100210528 | Compositions, methods and uses for inhibition and/or treatment of influenza infection Embodiments of the present invention illustrate methods and compositions for treating medical disorders. In certain embodiments, compositions and methods relate to reducing or inhibiting a the onset or development of a viral disorder.... | 08/19/2010 |
| 20100204157 | USE OF A PEPTIDE AS A THERAPEUTIC AGENT The present invention is directed to the use of the peptide compound Phe-Phe-Val-Ala-Pro as a therapeutic agent for the prophylaxis and/or treatment of cancer, autoimmune diseases, fibrotic diseases, inflammatory diseases, neurodegenerative diseases, infectious diseases... | 08/12/2010 |
| 20100204137 | THE USE OF SUBSTANCES FOR THE TREATMENT OF LOSS OF EYESIGHT IN HUMANS WITH GLAUCOMA AND OTHER DEGENERATIVE EYE DISEASES Methods for the prevention and treatment of ocular disorders, in particular glaucoma, through blocking the toxic effects of β-amyloid (Aβ) derivatives, and pharmaceutical compositions for effecting such prevention and treatment thereof.... | 08/12/2010 |
| 20100204147 | Methods For Delivering Thymosin Beta 4, Analogues, Isoforms and Other Derivatives A composition and method utilizes a substantially purified composition including an adhesive and a polypeptide containing amino acid sequence LKKTET or a conservative variant thereof.... | 08/12/2010 |
| 20100204158 | COMBINATION OF SPLENOPENTIN AND THYMOPENTIN AND THE USE THEREOF IN MEDICINE The present invention is directed to the use of the combination of the peptide compounds Arg-Lys-Glu-Val-Tyr-OH and Arg-Lys-Asp-Val-Tyr-OH as a therapeutic combination for prophylaxis and/or treatment of cancer, a heart and vascular disease, an infectious disease, a fib... | 08/12/2010 |
| 20100204155 | USE OF THE PEPTIDE SFLLR-OH AND MURAMYL DIPEPTIDE AS THERAPEUTIC AGENTS The present invention is directed to the use of the peptide compound Ser-Phe-Leu-Leu-Arg-OH as a therapeutic agent for the prophylaxis and/or treatment of cancer, autoimmune diseases, fibrotic diseases, inflammatory diseases, neurodegenerative diseases, infectious disea... | 08/12/2010 |
| 20100204154 | USE OF THE PEPTIDE RFMWMR AS A THERAPEUTIC AGENT The present invention is directed to the use of the peptide compound Ac-Arg-Phe-Met-Trp-Met-Arg-NH2 as a therapeutic agent for the prophylaxis and/or treatment of cancer, autoimmune diseases, fibrotic diseases, inflammatory diseases, neurodegenerative disease... | 08/12/2010 |
| 20100204153 | USE OF BAND 3 PROTEIN (824-829) AND/OR MELANOCYTE-STIMULATING HORMONE RELEASE-INHIBITING FACTOR AS A THERAPEUTIC AGENT IN THE TREATMENT OF PSEUDOMONAS AERUGINOSA INFECTION The present invention is directed to the use of the peptide compound Tyr-Val-Lys-Arg-Val-Lys-OH as a therapeutic agent for the prophylaxis and/or treatment of cancer, autoimmune diseases, fibrotic diseases, inflammatory diseases, neurodegenerative diseases, infectious d... | 08/12/2010 |
| 20100204156 | USE OF THYMOPENTIN AS A THERAPEUTIC AGENT The present invention is directed to the use of the peptide compound Arg-Lys-Asp-Val-Tyr-OH as a therapeutic agent for the prophylaxis and/or treatment of cancer, autoimmune diseases, fibrotic diseases, inflammatory diseases, neurodegenerative diseases, infectious disea... | 08/12/2010 |
| 20100197585 | USE OF A RGD-PEPTIDE AND/OR PARATHYROID HORMONE (1-34) AS ANTI-HIV AGENT The present invention is directed to the use of the peptide compound Gly-Arg-Gly-Asp-Asn-Pro as a therapeutic agent for the prophylaxis and/or treatment of cancer, autoimmune diseases, fibrotic diseases, inflammatory diseases, neurodegenerative diseases, infectious dise... | 08/05/2010 |
| 20100199361 | Role of Proteoglycans in Drug Dependence The invention provides methods of preventing or treating drug addiction, or ameliorating the craving for an addictive drug, as well as compounds, peptides, and pharmaceutical compositions that may be used to prevent or treat drug addiction or ameliorate the craving for ... | 08/05/2010 |
| 20100197607 | MUCIN HYPERSECRETION INHIBITORS AND METHODS OF USE Peptides are provided that comprise less than 24 amino acids. The peptides have an amino acid sequence selected from the group consisting of: (a) an amino acid sequence having from 4 to 6 contiguous amino acids of a reference sequence PEPTIDE 1; (b) an amino acid sequen... | 08/05/2010 |
| 20100197606 | NON-PROTEOLYSABLE OLIGOPEPTIDES THAT INHIBIT GLYCOPROTEIN GP41 OF THE AIDS VIRUS The invention relates to non-proteolysable oligopeptides that inhibit glycoprotein 41 of the AIDS virus. More specifically, the invention relates to the identification of oligopeptides, particularly hexapeptides, (D), (L) or mixed, preferably D-hexapeptides, which inhib... | 08/05/2010 |
| 20100197576 | Polypeptides or fusion proteins thereof inhibiting transmigration of leucocytes or growth and/or metastasis of cancer cells The present invention provides a polypeptide or its fusion protein derived from a paired immunoglobulin-like receptor α or β (PILRα or PILRβ), one of the transmembrane proteins, which inhibits the transmigration of leukocytes or the growth and/or metastasis of cance... | 08/05/2010 |
| 20100190710 | IL-23 RECEPTOR ANTAGONISTS AND USES THEREOF The present invention relates to IL-23 receptor antagonists and agonists. The use of IL-23 receptor antagonists in treating autoimmune and inflammatory disorders, as well as methods of identifying IL-23 receptor antagonists and agonists.... | 07/29/2010 |
| 20100190716 | USE OF A PLATELET FIBRINOGEN RECEPTOR HEXAPEPTIDE ANTAGONIST AND ALPHA-ENDORPHIN AS THERAPEUTIC AGENTS The present invention is directed to the use of the peptide compound Pro-Ser-Hyp-Gly-Asp-Trp-OH as a therapeutic agent for the prophylaxis and/or treatment of cancer, autoimmune diseases, fibrotic diseases, inflammatory diseases, neurodegenerative diseases, infectious d... | 07/29/2010 |
| 20100190718 | METHODS FOR PREVENTING OR TREATING MITOCHONDRIAL PERMEABILITY TRANSITION The invention provides a method of reducing or preventing mitochondrial permeability transitioning. The method comprises administering an effective amount of an aromatic-cationic peptide having at least one net positive charge; a minimum of four amino acids; a maximum o... | 07/29/2010 |
| 20100184704 | USE OF THE PEPTIDE GLY-ARG-GLY-ASP-ASN-PRO AS A THERAPEUTIC AGENT The present invention is directed to the use of the peptide compound Gly-Arg-Gly-Asp-Asn-Pro-OH as a therapeutic agent for the prophylaxis and/or treatment of cancer, autoimmune diseases, fibrotic diseases, inflammatory diseases, neurodegenerative diseases, infectious d... | 07/22/2010 |
| 20100184701 | Beta-Arrestin Effectors And Compositions And Methods Of Use Thereof This application describes a family of compounds acting as β-arrestin effectors. Such compounds may provide significant therapeutic benefit in the treatment of chronic and acute cardiovascular diseases.... | 07/22/2010 |
| 20100184702 | Selective High-Affinity Polydentate Ligands and Methods of Making Such This invention provides novel polydentate selective high affinity ligands (SHALs) that can be used in a variety of applications in a manner analogous to the use of antibodies. SHALs typically comprise a multiplicity of ligands that each bind different region son the tar... | 07/22/2010 |
| 20100184703 | USE OF PEPTIDE DERIVATIVES FOR TREATING PATHOLOGIES RESULTING FROM ISCHEMIA The inventors have studied the kinetic and hierarchy of activation of apoptogenic caspases during myocardial ischemia and have found that caspase 2 plays a major role during the cardiac pathology by a very fast activation after an ischemic episode. Experiments were carr... | 07/22/2010 |
| 20100184705 | Therapeutic Peptides and Vaccines Compositions are disclosed that induce broadly HIV therapeutic and vaccine inducing antibodies against diverse HIV clades and relate to the ability to identify HIV gp120-derived short peptide sequence immunogens and various therapeutic compositions made from the identif... | 07/22/2010 |
| 20100185219 | REINFORCED BIOLOGICAL MESH FOR SURGICAL REINFORCEMENT The invention is directed toward a composite material for use in a medical application, comprising a biological material and a reinforcement material. The biological material may be overlayed onto the reinforcement layer, or the material may be attached together. In one... | 07/22/2010 |
| 20100184696 | Peptides and Their Use The present invention relates to peptides for use as antifungal agents. The peptides comprise a sequence of 5 to 15 basic amino acids wherein substantially all of the amino acids in said sequence are the same.... | 07/22/2010 |
| 20100178324 | COMPOSITION AND METHOD FOR THE TREATMENT OF DISEASES AFFECTED BY APOPTOSIS The present invention includes methods of making and methods of using peptidomimetics compositions that mimic α-helical BH3 sequences in cells. The peptidomimetics can be used to mimic α-helical BH3 sequences and kill cancer cells.... | 07/15/2010 |
